4.7 Review

A model of interaction: Aflatoxins and hepatitis viruses in liver cancer aetiology and prevention

期刊

CANCER LETTERS
卷 286, 期 1, 页码 22-28

出版社

ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2009.02.053

关键词

Biomarkers; Chemical-viral interaction; Prevention

类别

资金

  1. NIEHS, USA [ES006052]
  2. NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES006052] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide and has an extremely poor prognosis. The majority of cases occur in south-east Asia and sub-Saharan Africa where the major risk factors are chronic infection with hepatitis B and C viruses (HBV and HCV) as well as dietary exposure to aflatoxins. Aflatoxin B1, the most commonly occurring and potent of the aflatoxins is associated with a specific AGG to AGT transversion mutation at codon 249 of the p53 gene in human HCC, providing mechanistic support to a causal link between exposure and disease. Prospective epidemiological studies have shown a more than multiplicative interaction between HBV and aflatoxins in terms of HCC risk. However, the biology underlying this statistical interaction is not fully understood. There are a number of potential mechanisms including, among others: the fixation of AFB1-induced mutations in the presence of liver regeneration and hyperplasia induced by chronic HBV infection; the predisposition of HBV-infected hepatocytes to aflatoxin-induced DNA damage; an increase in susceptibility to chronic HBV infection in aflatoxin-exposed individuals; and oxidative stress exacerbated by co-exposure to aflatoxins and chronic hepatitis infection. Priorities for prevention are global HBV vaccination, primary and secondary prevention strategies against aflatoxin and the avoidance of transmission of HCV through good hygiene practices. (C) 2009 Elsevier Ireland Ltd. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Roadmap for investigating epigenome deregulation and environmental origins of cancer

Zdenko Herceg, Akram Ghantous, Christopher P. Wild, Athena Sklias, Lavinia Casati, Susan J. Duthie, Rebecca Fry, Jean-Pierre Issa, Richard Kellermayer, Igor Koturbash, Yukata Kondo, Johanna Lepeule, Sheila C. S. Lima, Carmen J. Marsit, Vardhman Rakyan, Richard Saffery, Jack A. Taylor, Andrew E. Teschendorff, Toshikazu Ushijima, Paolo Vineis, Cheryl Lyn Walker, Robert A. Waterland, Joe Wiemels, Srikant Ambatipudi, Davide Degli Esposti, Hector Hernandez-Vargas

INTERNATIONAL JOURNAL OF CANCER (2018)

Article Public, Environmental & Occupational Health

EXPOsOMICS: final policy workshop and stakeholder consultation

Michelle C. Turner, Paolo Vineis, Eduardo Seleiro, Michaela Dijmarescu, David Balshaw, Roberto Bertollini, Marc Chadeau-Hyam, Timothy Gant, John Gulliver, Ayoung Jeong, Soterios Kyrtopoulos, Marco Martuzzi, Gary W. Miller, Timothy Nawrot, Mark Nieuwenhuijsen, David H. Phillips, Nicole Probst-Hensch, Jonathan Samet, Roel Vermeulen, Jelle Vlaanderen, Martine Vrijheid, Christopher Wild, Manolis Kogevinas

BMC PUBLIC HEALTH (2018)

Article Oncology

Tackling cancer burden in low-income and middle-income countries: Morocco as an exemplar

Farida Selmouni, Ahmed Zidouh, Latifa Belakhel, Catherine Sauvaget, Maria Bennani, Youssef Chami Khazraji, Abdellatif Benider, Christopher P. Wild, Rachid Bekkali, Ibtihal Fadhil, Rengaswamy Sankaranarayanan

LANCET ONCOLOGY (2018)

Article Oncology

Reducing Social Inequalities in Cancer: Setting Priorities for Research

Salvatore Vaccarella, Joannie Lortet-Tieulent, Rodolfo Saracci, Miranda M. Fidler, David I. Conway, Nadia Vilahur, Diana Sarfati, Ahmedin Jemal, Johan P. Mackenbach, Michael G. Marmot, Kurt Straif, Christopher P. Wild

CA-A CANCER JOURNAL FOR CLINICIANS (2018)

Article Public, Environmental & Occupational Health

Impaired growth in rural Gambian infants exposed to aflatoxin: a prospective cohort study

Sinead Watson, Sophie E. Moore, Momodou K. Darboe, Gaoyun Chen, Yu-Kang Tu, Yi-Ting Huang, Kamilla G. Eriksen, Robin M. Bernstein, Andrew M. Prentice, Christopher P. Wild, Ya Xu, Michael N. Routledge, Yun Yun Gong

BMC PUBLIC HEALTH (2018)

Article Nutrition & Dietetics

Trends of serum phospholipid fatty acids over time in rural Uganda: evidence of nutritional transition?

Veronique Chajes, Lorna J. Gibson, Carine Biessy, Nadia Slimani, Gershim Asiki, Laure Dossus, Christopher P. Wild, Robert Newton

BRITISH JOURNAL OF NUTRITION (2019)

Review Oncology

Primary prevention: a need for concerted action

Joachim Schuz, Carolina Espina, Christopher P. Wild

MOLECULAR ONCOLOGY (2019)

Review Oncology

Cancer Prevention Europe

Christopher P. Wild, Carolina Espina, Linda Bauld, Bernardo Bonanni, Hermann Brenner, Karen Brown, Joakim Dillner, David Forman, Ellen Kampman, Mef Nilbert, Karen Steindorf, Hans Storm, Paolo Vineis, Michael Baumann, Joachim Schuez

MOLECULAR ONCOLOGY (2019)

Editorial Material Oncology

Boosting the social impact of innovative cancer research - towards a mission-oriented approach to cancer

Ulrik Ringborg, Julio E. Celis, Michael Baumann, Alexander Eggermont, Christopher P. Wild, Anton Berns

MOLECULAR ONCOLOGY (2019)

Article Cell Biology

Centralization of the IARC Biobank: Combining Multiple Sample Collections into a Common Platform

Maimuna Mendy, Elodie Caboux, Christopher P. Wild, Rolando Herrero, Rosita Accardi-Gheit, Gary Clifford, Elisabeth Francon, Ausrele Kesminiene, James Mckay, Sabina Rinaldi, Augustin Scalbert, Ghislaine Scello, Eduardo Seleiro, Jiri Zavadil

BIOPRESERVATION AND BIOBANKING (2019)

Article Oncology

The IARC Monographs: Updated Procedures for Modern and Transparent Evidence Synthesis in Cancer Hazard Identification

Jonathan M. Samet, Weihsueh A. Chiu, Vincent Cogliano, Jennifer Jinot, David Kriebel, Ruth M. Lunn, Frederick A. Beland, Lisa Bero, Patience Browne, Lin Fritschi, Jun Kanno, Dirk W. Lachenmeier, Qing Lan, Gerard Lasfargues, Frank Le Curieux, Susan Peters, Pamela Shubat, Hideko Sone, Mary C. White, Jon Williamson, Marianna Yakubovskaya, Jack Siemiatycki, Paul A. White, Kathryn Z. Guyton, Mary K. Schubauer-Berigan, Amy L. Hall, Yann Grosse, Veronique Bouvard, Lamia Benbrahim-Tallaa, Fatiha El Ghissassi, Beatrice Lauby-Secretan, Bruce Armstrong, Rodolfo Saracci, Jiri Zavadil, Kurt Straif, Christopher P. Wild

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2020)

Meeting Abstract Oncology

The global impact of environmental carcinogenesis and interventions for prevention

Christopher P. Wild

CANCER PREVENTION RESEARCH (2020)

Meeting Abstract Pathology

Morphological features of liver biopsies from The Gambia, West Africa: first pathology report from the Gambia Hepatitis Intervention Study by the International Agency for Research on Cancer

B. Abedi-Ardekani, D. Nasrollahzadeh, R. Njie, S. O. Bittaye, C. Carreira, M. Salieu Jallow, M. Almonte, C. P. Wild

VIRCHOWS ARCHIV (2019)

Article Surgery

Prevention of Proximal Junctional Kyphosis & Failure Using Sublaminar Bands in a Hybrid Construct in Pediatric Kyphosis Deformity

Christopher Battista, Christopher Wild, Sarah Kreul, Michael Albert

INTERNATIONAL JOURNAL OF SPINE SURGERY (2018)

Review Health Policy & Services

Time for a European initiative for research to prevent cancer: A manifesto for Cancer Prevention Europe (CPE)

David Forman, Linda Bauld, Bernardo Bonanni, Hermann Brenner, Karen Brown, Joakim Dillner, Ellen Kampman, Marta Manczuk, Elio Riboli, Karen Steindorf, Hans Storm, Carolina Espina, Christopher P. Wild

JOURNAL OF CANCER POLICY (2018)

Review Oncology

Small extracellular vesicles: Non-negligible vesicles in tumor progression, diagnosis, and therapy

Xinru Zhou, Yin Jia, Chuanbin Mao, Shanrong Liu

Summary: Small extracellular vesicles (sEVs), such as exosomes, have emerged as crucial targets for liquid biopsy and promising drug delivery vehicles in tumor progression. They can serve as biomarkers for tumor diagnosis and as drug carriers for cancer treatment.

CANCER LETTERS (2024)

Article Oncology

HMGB1 in the interplay between autophagy and apoptosis in cancer

Ruochan Chen, Ju Zhu, Xiao Zhong, Jie Li, Rui Kang, Daolin Tang

Summary: The interplay between autophagy and apoptosis plays a crucial role in tumorigenesis and cancer therapy, with HMGB1 serving as a key regulator in these processes.

CANCER LETTERS (2024)

Article Oncology

Epigenetic inhibition of CTCF by HN1 promotes dedifferentiation and stemness of anaplastic thyroid cancer

Zongfu Pan, Xixuan Lu, Tong Xu, Jinming Chen, Lisha Bao, Ying Li, Yingying Gong, Yulu Che, Xiaozhou Zou, Zhuo Tan, Ping Huang, Minghua Ge

Summary: This study uncovered the emerging role of HN1 in promoting dedifferentiation of anaplastic thyroid cancer (ATC) cells. HN1 negatively regulated the thyroid differentiation markers and had an inhibitory effect on the transcriptional activation of CTCF, thereby influencing the chromatin accessibility of thyroid differentiation genes.

CANCER LETTERS (2024)

Article Oncology

Autophagy machinery in glioblastoma: The prospect of cell death crosstalk and drug resistance with bioinformatics analysis

Yi Qin, Shengjun Xiong, Jun Ren, Gautam Sethi

Summary: Autophagy plays an important regulatory role in glioblastoma, and its dysregulation can lead to drug resistance and radioresistance. It also affects stem cell characteristics, overall growth, and metastasis. Therefore, autophagy is a promising target for glioblastoma therapy.

CANCER LETTERS (2024)

Article Oncology

Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase

Katsuya Nagaoka, Xuewei Bai, Dan Liu, Kevin Cao, Joud Mulla, Chengcheng Ji, Hongze Chen, Muhammad Azhar Nisar, Amalia Bay, William Mueller, Grace Hildebrand, Jin-Song Gao, Shaolei Lu, Hiroko Setoyama, Yasuhito Tanaka, Jack R. Wands, Chiung-Kuei Huang

Summary: This study found that serum 2-OG levels in cholangiocarcinoma patients are associated with the effectiveness of chemotherapy. Patients with progressive disease showed significantly higher levels of serum 2-OG compared to stable disease and partial response patients. The study also revealed that overexpression of ASPH mimics the effects of 2-OG, and knockdown of ASPH improves chemotherapy. Targeting ASPH enhances the effects of chemotherapy by modulating ATM and ATR, two key regulators of DDRs.

CANCER LETTERS (2024)